Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large number of Food and Drug Administration (FDA)-approved drugs have been found to inhibit the cell entry of Ebola virus (EBOV). However, since these drugs have various primary pharmacological targets, their mechanisms of action against EBOV remain largely unknown. We have previously shown that six FDA-approved drugs inhibit EBOV infection by interacting with and destabilizing the viral glycoprotein (GP). Here we show that antidepressants imipramine and clomipramine and antipsychotic drug thioridazine also directly interact with EBOV GP and determine the mode of interaction by crystallographic analysis of the complexes. The compounds bind within the same pocket as observed for other, chemically divergent complexes but with different binding modes. These details should be of value for the development of potent EBOV inhibitors.

Original publication

DOI

10.1021/acs.jmedchem.8b00350

Type

Journal article

Journal

J Med Chem

Publication Date

14/06/2018

Volume

61

Pages

4938 - 4945

Keywords

Antidepressive Agents, Tricyclic, Antipsychotic Agents, Binding Sites, Drug Design, Ebolavirus, Glycoproteins, Models, Molecular, Protein Binding, Protein Conformation, Viral Proteins